NCT00707967View on ClinicalTrials.gov

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

May 27, 2009

Study Completion Date

May 27, 2009

Conditions
Tuberculosis
Interventions
BIOLOGICAL

GSK's candidate Mycobacterium tuberculosis vaccine 692342

Intramuscular injection, 2 doses at 0, 1 month

BIOLOGICAL

Control vaccine with the adjuvant system.

Intramuscular injection, 2 doses at 0, 1 month

BIOLOGICAL

Control vaccine with physiological saline

Intramuscular injection, 2 doses at 0, 1 month

Trial Locations (1)

1011

GSK Investigational Site, Lausanne

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00707967 - Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults. | Biotech Hunter | Biotech Hunter